|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In PFC, the expression ratio of DARPP-32/CaN were significantly lower in schizophrenia than controls.
|
31619735 |
2019 |
|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we assessed the effect of this polymorphism on DARPP-32 and CaN protein expression in the postmortem striatum of patients with schizophrenia and control individuals.
|
29627696 |
2018 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
We propose that DARPP-32 and its interacting proteins may serve as potential therapeutic targets in the treatment of schizophrenia.
|
28881851 |
2017 |
|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Altered expression of DARPP-32 and its truncated isoform (t-DARPP), specifically in the prefrontal cortex, has been associated with schizophrenia and bipolar disorder.
|
26872373 |
2016 |
|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We used immunoblotting techniques and postmortem tissue samples from patients with schizophrenia and from normal control individuals to examine the expression of two major DARPP-32 isoforms, full-length (FL-DARPP) and truncated (t-DARPP), and of CaN in the striatum.
|
24704945 |
2014 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Our results suggest that variation in PPP1R1B affects the abundance of the splice variant t-DARPP-32 mRNA and may reflect potential molecular mechanisms implicated in schizophrenia and affective disorders.
|
23295814 |
2014 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
PSYGENET |
We used immunoblotting techniques and postmortem tissue samples from patients with schizophrenia and from normal control individuals to examine the expression of two major DARPP-32 isoforms, full-length (FL-DARPP) and truncated (t-DARPP), and of CaN in the striatum.
|
24704945 |
2014 |
|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that variation in PPP1R1B affects the abundance of the splice variant t-DARPP-32 mRNA and may reflect potential molecular mechanisms implicated in schizophrenia and affective disorders.
|
23295814 |
2014 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
RGD |
Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens.
|
22820052 |
2012 |
|
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analysis of allele and genotype frequencies in these two groups revealed no significant association of BDNF or DARPP-32 polymorphisms with schizophrenia in Malays.
|
22576830 |
2012 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
PSYGENET |
We compared the density of immunoreactive cells of the STG (BA22) from 11 schizophrenia patients with those from 11 age- and sex-matched controls, and found significantly lower densities of DARPP-32-immunoreactive (IR) cells and threonine (Thr) 34-phosphorylated DARPP-32-IR cells in the STG in the schizophrenia group.
|
21453742 |
2011 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
We compared the density of immunoreactive cells of the STG (BA22) from 11 schizophrenia patients with those from 11 age- and sex-matched controls, and found significantly lower densities of DARPP-32-immunoreactive (IR) cells and threonine (Thr) 34-phosphorylated DARPP-32-IR cells in the STG in the schizophrenia group.
|
21453742 |
2011 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
our data suggest: (i) C14ORF28, GNB2L1, MLLT3, DRD2 and DARPP-32 are important in the pathogenesis of schizophrenia and bipolar disorder; (ii) these two disorders share common disease-related mechanisms linked to dopamine signalling; (iii) the expression of these genes is closely correlated; and (iv) DRD2 provides the initial trigger in the pathogenesis of these disorders.
|
20874815 |
2011 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that the decrease in DARPP-32 in schizophrenia was more marked in neurons of DLPFC than in other cells or other brain regions, and that this decrease might be partly compensated for by an increase in expression of Thr34-phosphorylated DARPP-32 in DLPFC.
|
22179181 |
2011 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
PSYGENET |
These results suggest that the decrease in DARPP-32 in schizophrenia was more marked in neurons of DLPFC than in other cells or other brain regions, and that this decrease might be partly compensated for by an increase in expression of Thr34-phosphorylated DARPP-32 in DLPFC.
|
22179181 |
2011 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
PSYGENET |
our data suggest: (i) C14ORF28, GNB2L1, MLLT3, DRD2 and DARPP-32 are important in the pathogenesis of schizophrenia and bipolar disorder; (ii) these two disorders share common disease-related mechanisms linked to dopamine signalling; (iii) the expression of these genes is closely correlated; and (iv) DRD2 provides the initial trigger in the pathogenesis of these disorders.
|
20874815 |
2011 |
|
Schizophrenia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent work on DAOA, PPP1R1B, and APOL1 suggests that these genes present common alleles associated to increase risk of schizophrenia but conferring an overall selective advantage, related to better cognitive performance (DAOA and PPP1R1B) or protection against pathogens (APOL1).
|
20483474 |
2010 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent findings have highlighted the importance of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, 32 kDa), a key regulatory molecule in the dopaminergic signalling pathway for dopamine related phenotypes like antisocial-behavior, drug addiction and schizophrenia.
|
19463699 |
2009 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
LHGDN |
Our findings suggest that PPP1R1B SNPs are unlikely to be related to the development of schizophrenia and bipolar disorder in the Japanese population.
|
18055181 |
2008 |
|
Schizophrenia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We performed RT-PCR to quantify DARPP-32 mRNA from brain samples (Brodmann Area 46) donated by the Stanley Medical Research Institute (SMRI, Array Collection): 35 from unaffected controls (UC), 35 from patients with schizophrenia (SCZ), and 35 with bipolar disorder (BP).
|
18573638 |
2008 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PPP1R1B SNPs are unlikely to be related to the development of schizophrenia and bipolar disorder in the Japanese population.
|
18055181 |
2008 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our convergent results identify a prefrontal-neostriatal system affected by variation in PPP1R1B and suggest that DARPP-32 plays a pivotal role in cognitive function and possibly in the pathogenesis of schizophrenia.
|
17290303 |
2007 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
LHGDN |
Our convergent results identify a prefrontal-neostriatal system affected by variation in PPP1R1B and suggest that DARPP-32 plays a pivotal role in cognitive function and possibly in the pathogenesis of schizophrenia.
|
17290303 |
2007 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further functional analysis and genetic association studies are needed to determine the potential roles of PPP1R1B and other related genes in the pathophysiology of schizophrenia.
|
17618027 |
2007 |
|
Schizophrenia
|
0.600 |
Biomarker
|
disease |
LHGDN |
The present study suggests that DARPP-32 decreases in the DLPFC of patients with schizophrenia and bipolar disorder, and further suggests that this decrease is associated with dysfunction of dopaminoceptive neurons in the DLPFC of patients affected by these two mental disorders.
|
17521792 |
2007 |